OR WAIT null SECS
Pfizer agrees to divest four sterile injectable assets to clear the way to complete acquisition of Hospira.
Pfizer announced on Aug. 24, 2015 that the US Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira, contingent upon Pfizer’s commitment to divest four US sterile injectable assets, including acetylcysteine, clindamycin, voriconazole, and melphalan.
Pfizer also announced that Brazil’s Superintendency-General of CADE has published its unconditional clearance decision.
In a press statement, Pfizer reported an anticipated transaction close in early September.